A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of multiple, ascending doses of PF-04958242 administered orally to psychiatrically stable subjects with schizophrenia receiving antipsychotic and adjunctive medication.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Biogen; Pfizer

Criteria

Inclusion Criteria:

• Psychiatrically stable subjects with schizophrenia

• Evidence of stable schizophrenia symptomatology ≥ 3 months

• Score on MCCB Letter-number span + Spatial span subtest < 40.

Exclusion Criteria:

• History of seizures or of a condition with risk of seizures

• History of abnormal EEG.

• Pregnant or nursing females, and women of child bearing potential